{
    "nctId": "NCT03025711",
    "briefTitle": "Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine",
    "officialTitle": "Use Of Pertuzumab And Trastuzumab Emtansine In Adult Patients With Her2-Positive Metastatic Or Locally Recurrent Unresectable Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 220,
    "primaryOutcomeMeasure": "Overall survival.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patients (age \u2265 18 years at enrolment) with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Trastuzumab emtansine (T-DM1) or Pertuzumab.\n* Patients who initiate Trastuzumab emtansine (T-DM1) and Pertuzumab under Spanish compassionate use or early access program.\n\nExclusion Criteria:\n\n* Given the characteristics of the study there are no exclusion criteria.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}